(-)-Deprenyl a selective MAO "B' inhibitor, increases [3H]imipramine binding and decreases beta-adrenergic receptor function.
In rats, a selective inhibition for 3 weeks of monoamineoxydase (MAO) type B elicited by daily doses of pargyline (2.5 mumol/kg) or (-)-deprenyl (1 mumol/kg) attenuated the NE dependent stimulation of cortical adenylate cyclase and reduced the number of brain recognition sites for beta-adrenergic receptor ligands. Similar actions were not elicited by a comparable dose regimen of (+)-amphetamine. Hence the inhibition of MAO B mimicks responses that are typically elicited by antidepressants. The molecular nature of the mechanisms involved cannot be understood, however, these mechanisms may not be identical for pargyline and (-)-deprenyl because this drug but not pargyline increased the number of [3H]imipramine recognition sites. Even high daily doses of pargyline (100 mumol/kg, for 3 weeks) failed to change [3H]imipramine binding though they still down regulated beta-adrenergic recognition sites, the NE stimulation of adenylate cyclase and the Bmax of [3H]mianserin and [3H]spiroperidol binding.
D000818:Animals; D003913:Dextroamphetamine / Q000494:pharmacology; D006624:Hippocampus / Q000378:metabolism; D007099:Imipramine / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D010293:Pargyline / Q000494:pharmacology; D010627:Phenethylamines / Q000494:pharmacology*; D011485:Protein Binding; D051381:Rats; D011919:Rats, Inbred Strains; D011941:Receptors, Adrenergic / Q000187:drug effects*; D011943:Receptors, Adrenergic, beta / Q000187:drug effects* / Q000378:metabolism; D012642:Selegiline / Q000494:pharmacology*; D013570:Synaptic Membranes / Q000378:metabolism
D010627:Phenethylamines; D011941:Receptors, Adrenergic; D011943:Receptors, Adrenergic, beta; D012642:Selegiline; D010293:Pargyline; D007099:Imipramine; D003913:Dextroamphetamine; D009638:Norepinephrine